Cancer cell migration was assessed using the Oris™ cell migration kit (Platypus), as previously described [8 (link)]. The (TCM-LEC)CM (100 μl) with or without 20 μM maraviroc (R&D Systems) or 200 μg/ml tocilizumab (Genentech) was added once the cancer cells had attached. Migration and proliferation assays using CIM (cell invasion and migration) plates and the RTCA system (ACEA Bioscience) were performed as previously described [9 (link)].
Free full text: Click here